The Technical Analyst
Moleculin Biotech Inc [MBRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Moleculin Biotech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.35% $4.40
America/New_York / 24 apr 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.80 mill |
| EPS: | -15.15 |
| P/E: | -0.290 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 2.23 mill |
| Avg Daily Volume: | 0.116 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.290 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.05x |
| Company: PE -0.290 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$11.63 (164.31%) $7.23 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.55 - 5.25 ( +/- 19.36%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-26 | Foster Jonathan P. | Buy | 28 986 | Common Stock |
| 2023-12-26 | George Robert E. | Buy | 14 493 | Common Stock |
| 2023-12-26 | Klemp Walter V | Buy | 188 404 | Common Stock |
| 2023-07-11 | Klemp Walter V | Sell | 13 204 | Restricted Stock Units |
| 2023-07-11 | Klemp Walter V | Buy | 13 204 | Common Stock |
| INSIDER POWER |
|---|
| 83.11 |
| Last 98 transactions |
| Buy: 6 351 373 | Sell: 471 392 |
Forecast:
16:00 - $4.40
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.40
Forecast 2: 16:00 - $4.40
Forecast 3: 16:00 - $4.40
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.40 (-4.35% ) |
| Volume | 0.0070 mill |
| Avg. Vol. | 0.116 mill |
| % of Avg. Vol | 6.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MBRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MBRX
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Latest Press Releases
2024-04-22 07:00:50 - Press Release
Prism Marketview – Biotech Breakfast
Roche's alecensa gets fda green light; immunitybio gains as pdufa date approaches for bladder cancer drug; key drug trial failures in 2024 new york, n.y., april 22, 2024 – prism marketview – healthcare equities finished mostly higher after a very quiet trading session on friday.
2024-04-18 08:30:00 - Press Release
European Medicines Agency (ema) Grants Orphan Drug Designation For Moleculin's Treatment Of Acute Myeloid Leukemia (aml)
– next-generation non-cardiotoxic anthracycline annamycin with notable signs of clinical efficacy in aml in combination with cytarabine achieves preliminary crc rate of 60% in 2nd line aml subjects in a european clinical trial – there are approximately 160,000 people with aml worldwide – annamycin continues to show no signs of cardiotoxicity (n=82 across multiple studies); lower toxicity profile than traditional intensive therapy – annamycin is advancing towards pivotal aml study in 2024 and may qualify for an accelerated approval pathway houston , april 18, 2024 /prnewswire/ -- moleculin biotech, inc. , (nasdaq: mbrx) (moleculin or the company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the european medicines agency (ema) has granted orphan drug designation to annamycin for the treatment of aml...
2024-04-10 08:30:00 - Press Release
Moleculin Announces Presentation Of Positive Data Demonstrating High Anti-cancer Activity Of Annamycin And Non-cardiotoxic Properties
Annamycin demonstrated to be a more potent inhibitor of topoisomerase ii-alpha and ii-beta while remaining inactive against established cardiomyocyte cultures results clearly aligned with lack of drug-related cardiotoxic events in patients treated with annamycin in ongoing clinical trials; 100% of annamycin subjects in multiple studies (n=82) continue to show no signs of cardiotoxicity during study a prominent treatment for many adult cancers and approximately 50% of all pediatric cancer patients are treated with a cardiotoxic anthracycline annamycin composition of matter patent issued april 9 th; patent enables expansion into greater patient populations where cardiotoxicity remains an unmet need houston , april 10, 2024 /prnewswire/ -- moleculin biotech, inc...
2024-03-28 10:45:00 - Press Release
Moleculin To Present At The Medinvest Biotech & Pharma Investor Conference
Live webcast on thursday, april 4 th at 4:10 pm et houston, march 28, 2024 /prnewswire/ -- moleculin biotech, inc. , (nasdaq: mbrx) (moleculin or the company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced walter klemp, president and chief executive officer of moleculin will present at the medinvest biotech & pharma investor conference behind held in new york city, ny on thursday, april 4, 2024 at 4:10 pm et. in addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
2024-03-27 09:25:00 - Press Release
Moleculin To Participate In The Virtual Investor Lunch Break: The Moleculin Opportunity
Live webcast with walter klemp, chairman and chief executive officer, on thursday, march 28 th at 12:00 pm et houston , march 27, 2024 /prnewswire/ -- moleculin biotech, inc. , (nasdaq: mbrx) (moleculin or the company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the virtual investor lunch break: the moleculin opportunity event on thursday, march 28, 2024 at 12:00 pm et. as part of the event, walter klemp, chairman and chief executive officer of moleculin, will provide a corporate overview, business outlook, and discuss the moleculin opportunity.
Latest News
2024-03-25 11:25:19 - Seeking Alpha
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
2024-03-12 09:05:00 - PRNewsWire
Moleculin to Present at the 36th Annual ROTH Conference
Live webcast fireside chat on Monday, March 18 th at 9:00 AM PT HOUSTON , March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT. In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
2023-11-14 12:02:18 - Zacks Investment Research
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
2023-11-07 08:45:00 - PRNewsWire
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast
HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that it will report its financial results for the third quarter ended September 30, 2023, on Monday November 13, 2023. Moleculin management will host a conference call and live webcast to discuss the operational and financial results at 8:30 AM ET that same day.
2023-09-22 09:01:11 - Zacks Investment Research
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
2023-09-15 08:24:58 - InvestorPlace
Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?
Moleculin Biotech (NASDAQ: MBRX ) stock is on the move Friday after the clinical-stage pharmaceutical company provided an update to investors. According to a press release from Moleculin Biotech, the company is preparing to attend the 2023 CTOS Annual Meeting.
2023-09-05 08:35:00 - PRNewsWire
Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON , Sept. 5, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will present at the H.C.
2023-08-11 10:08:06 - Seeking Alpha
Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q2 2023 Earnings Call Transcript August 11, 2023 8:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman & CEO John Paul Waymack - Senior CMO Jonathan Foster - EVP & CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Jeff Jones - Oppenheimer Operator Hello, and welcome to the Moleculin Biotech Quarterly Update Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
2023-08-03 08:45:00 - PRNewsWire
Moleculin to Report Second Quarter Financial Results on August 11, 2023 and Host Conference Call and Webcast
HOUSTON , Aug. 3, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the second quarter ended June 30, 2023, on Friday, August 11, 2023. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day.
2023-06-13 08:35:00 - PRNewsWire
Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Live webcast fireside chat on Wednesday, June 21 st at 1:30 PM ET HOUSTON , June 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer and Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Wednesday, June 21, 2023 at 1:30 PM ET. The exponential growth in knowledge and expertise in science and medicine continues to drive opportunities in the healthcare space.